Research digest / 04 · oral-precursor channel
Nicotinamide Riboside (NR): NAD+ Precursor Research
The most clinically studied oral NAD+ booster, read through its dose-response — a +22% / +51% / +142% whole-blood NAD+ amplitude meter, cited to source.
In plain English
Nicotinamide riboside (NR) is a precursor — a building block the body converts into NAD+, the fuel-handling helper molecule every cell uses. It is a member of the vitamin-B3 family, and it is the oral NAD+ booster with the most clinical-trial evidence behind it. The headline result is clean: when healthy adults took NR for eight weeks, the NAD+ measured in their blood rose step by step with the dose — about 22%, then 51%, then 142% as the dose went up. It was well tolerated, with no flushing. What is still open is whether that blood rise changes long-term health. This page reports the studies, not advice.
What nicotinamide riboside is
Nicotinamide riboside (NR) is a vitamin-B3-family NAD+ precursor (CAS 1341-23-7). Inside the cell it is converted to NMN by the NRK1/NRK2 kinases, then to NAD+ — a route that bypasses the Preiss-Handler pathway used by niacin [5]. That direct entry into the salvage-adjacent route, plus a clean tolerability profile, is why NR is the most clinically studied oral NAD+ booster. It carries an ORAL-PRECURSOR channel tag throughout this site: an NR trial measures the effect of a precursor the body turns into NAD+, never the effect of swallowing NAD+ itself, which is poorly absorbed [5].
The NR dose-response: +22% / +51% / +142%
The defining NR result is a dose-response. In a randomized, double-blind, placebo-controlled trial of healthy overweight adults, NR at 100, 300 and 1000 mg/day for 8 weeks raised whole-blood NAD+ by 22%, 51% and 142% respectively, and the elevation was maintained throughout the study [4]. Critically, NR did not cause flushing — the limiting side effect of high-dose niacin — and showed no significant adverse-event difference from placebo at any dose, no rise in LDL cholesterol, and no disruption of one-carbon metabolism [4]. This establishes oral NR as a well-tolerated, dose-scalable way to raise blood NAD+. It is the cleanest demonstration in the literature that an oral precursor moves the coenzyme dose-dependently in humans.
NR safety at high doses
NR's tolerability extends to high doses. Beyond the 8-week dose-ranging trial [4], NR has been examined at up to 3000 mg/day for safety in a Parkinson's-disease setting (the NR-SAFE line of work), part of why it anchors the high-dose end of the precursor record. Across the controlled oral-NR literature, adverse events have been generally mild and comparable to placebo [4]. As with every entry here, this reports what trials observed in their populations — it is not a recommendation to use NR at any dose, and the high-dose findings describe safety endpoints, not efficacy claims.
NR within the age-decline picture
NR matters because tissue NAD+ falls with age — on the order of ~50% in human skin and brain by mid-to-late life [6] — and the maintenance enzymes that depend on NAD+ (sirtuins) are rate-limited by how much is available [8]. Raising NAD+ via precursors is the strategy that follows from that biology [7]. NR reliably accomplishes the first step — lifting blood NAD+ — which is settled [4]. The unsettled step is translation: a 2025 review concluded that human efficacy for hard clinical endpoints remains limited and tissue-NAD+ data sparse, and that much of the strongest anti-aging signal still comes from rodents [14]. NR is therefore best read as a confirmed NAD+ booster whose downstream clinical value is still being established. Compare the NMN in aging research record for the sibling precursor.